Hikma Pharmaceuticals PLC (HKMPY)
- Stockopedia
Two major factors that could drive the Hikma Pharmaceuticals share price
Shares in Hikma Pharmaceuticals (LON:HIK) are currently trading at 1,727p, but a key question for investors is how much the current economic uncertainty will a...
- Simply Wall St.
Investors in Hikma Pharmaceuticals (LON:HIK) have unfortunately lost 26% over the last year
It's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly...
- Reuters
Drugmaker Hikma drops on slashing generics unit forecasts
The London-listed drugmaker now expects revenue from its generics unit to be between $710 million and $750 million for 2022, with core operating margin of around 20%. The revised outlook comes in stark contrast to the company's trading statement last week, when it had forecasted revenue from the business to grow 8% to 10% over 2021 sales of $820 million and predicted core operating margin in the range of 24% to 25%. FTSE 100-listed shares of Hikma, which supplies many generic drugs including pain medications, anaesthetics and sedatives, were down 9.6% at 1,667.5 pence by 0739 GMT and were the biggest loser on the UK blue-chip index.
